The role of neoadjuvant (HER)2-targeted therapies in (HER)2-overexpressing breast cancers.

ABSTRACT: Women receiving neoadjuvant systemic therapy for primary operable or inoperable breast cancer can potentially benefit in a number of ways, but the main advantage, which has been consistently demonstrated, is improved tumour resectability. Given the improvement in outcomes with the adjuvant use of trastuzumab in patients with early-stage breast cancer positive for the human epidermal growth factor receptor 2 (HER2), questions have been raised about the use of trastuzumab in the neoadjuvant setting. The present paper reviews the currently available data and outlines suggestions from a panel of Canadian oncologists about the use of trastuzumab and other HER2-targeted agents in the neoadjuvant setting.The panel focussed on the use of trastuzumab and other HER2-targeted agents as neoadjuvant th

SUBMITTER: Lemieux J 

PROVIDER: S-EPMC2768514 | biostudies-literature | 2009 Sep

REPOSITORIES: biostudies-literature